Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 93Breast 48Head & Neck 8Tumor-Agnostic 7Other solid neoplasm 7Thoracic 4Gynecologic 4Genitourinary 1Endocrine 1

Conditions

Somatostatinoma 1Carcinoma, Neuroendocrine 1

Interventions

Magnetic Resonance Spectroscopy 15Specimen Handling 14lutetium Lu 177 dotatate 13Nivolumab 11cabozantinib 10Everolimus 9pembrolizumab 8gallium Ga 68 dotatate 7Ipilimumab 6Cisplatin 6Carboplatin 6Etoposide 5trametinib 4olaparib 4lenvatinib 4X-Rays 4Lutetium-177 4CTLA-4 Antigen 4fluorodopa F 18 3dabrafenib 3cemiplimab 3Surveys and Questionnaires 3Phantoms, Imaging 3Immunoglobulin G 3Fluorodeoxyglucose F18 3Disulfides 3Cyclophosphamide 3Blood Specimen Collection 3177Lu-octreotide, DOTA(0)-Tyr(3)- 3selpercatinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Capecitabine × Endocrine × 90 days × Clear all
NCT02595424 2026-05-01

Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas

Eastern Cooperative Oncology Group

Phase 2 Active not recruiting
67 enrolled 13 charts
Endocrine

Somatostatinoma, Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon âš¡